ANGLE has completed a placing of new ordinary shares
ANGLE Plc has raised funds to develop the company.
ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.
Talk to the deal team
Related deals
Cerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreGewiss S.p.A. has completed a mandatory public tender offer for Beghelli S.p.A.
Gewiss S.p.A. has successfully finalized a mandatory public tender offer for Beghelli S.p.A.
Learn more